NYSEAMERICAN:LCTX Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis $1.12 +0.06 (+5.19%) As of 12:33 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LCTX alerts:Sign Up Key Stats Today's Range$1.05▼$1.1350-Day Range$1.03▼$1.3552-Week Range$0.95▼$2.09Volume461,436 shsAverage Volume1.30 million shsMarket Capitalization$277.97 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company Overview Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations. Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration. In parallel, Lineage is advancing oligodendrocyte progenitor cell therapies for spinal cord injury and conducting early-stage programs in immune-effector cell oncology, including dendritic cell-based vaccines and natural killer-cell products intended to stimulate or enhance anti-tumor responses. Founded in the 1990s as BioTime and rebranded in late 2019, Lineage Cell Therapeutics is headquartered in Carlsbad, California, with research and development activities extending into clinical sites across the United States and Europe. The company’s leadership team is led by President and Chief Executive Officer Brian Culley, supported by an experienced scientific advisory board. Through its integrated development strategy, Lineage aims to translate stem cell science into scalable therapies that address significant unmet medical needs in ophthalmology, neurology and oncology.AI Generated. May Contain Errors. Read More Lineage Cell Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreLCTX MarketRank™: Lineage Cell Therapeutics scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.Upside PotentialLineage Cell Therapeutics has a consensus price target of $6.25, representing about 460.5% upside from its current price of $1.12.Amount of Analyst CoverageLineage Cell Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Lineage Cell Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.07) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lineage Cell Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lineage Cell Therapeutics is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLineage Cell Therapeutics has a P/B Ratio of 5.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lineage Cell Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.91% of the float of Lineage Cell Therapeutics has been sold short.Short Interest Ratio / Days to CoverLineage Cell Therapeutics has a short interest ratio ("days to cover") of 34.65, which indicates bearish sentiment.Change versus previous monthShort interest in Lineage Cell Therapeutics has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLineage Cell Therapeutics does not currently pay a dividend.Dividend GrowthLineage Cell Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest2 people have searched for LCTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lineage Cell Therapeutics' insider trading history. Receive LCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LCTX Stock News HeadlinesLineage Cell Therapeutics maps COR1 path with 'thaw and inject' cell therapy planJuly 14, 2026 | msn.comLineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease TranscriptJuly 13, 2026 | seekingalpha.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.July 30 at 1:00 AM | Banyan Hill Publishing (Ad)Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh CoverageJune 20, 2026 | finance.yahoo.comHow The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst TargetsJune 4, 2026 | finance.yahoo.comLineage Cell Therapeutics (LCTX) price target increased by 14.58% to 5.61May 14, 2026 | msn.comLineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...May 13, 2026 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comSee More Headlines LCTX Stock Analysis - Frequently Asked Questions How have LCTX shares performed this year? Lineage Cell Therapeutics' stock was trading at $1.67 at the beginning of 2026. Since then, LCTX stock has decreased by 33.2% and is now trading at $1.1150. How were Lineage Cell Therapeutics' earnings last quarter? Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.01. The firm earned $1.73 million during the quarter, compared to analyst estimates of $3.60 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 89.36% and a negative net margin of 434.44%. Read the conference call transcript. Who are Lineage Cell Therapeutics' major shareholders? Top institutional investors of Lineage Cell Therapeutics include Defender Capital LLC. (2.65%). Insiders that own company stock include Broadwood Partners, LP, Brian M Culley, Don M Bailey and Jill Ann Howe. View institutional ownership trends. How do I buy shares of Lineage Cell Therapeutics? Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lineage Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Moderna (MRNA), JPMorgan Chase & Co. (JPM) and Chevron (CVX). Company Calendar Last Earnings5/12/2026Today7/30/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 2 weeks, LCTX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:LCTX CIK876343 Webwww.lineagecell.com Phone(442) 287-8963Fax510-521-3389Employees60Year FoundedN/APrice Target and Rating Average Price Target for Lineage Cell Therapeutics$6.25 High Price Target$9.00 Low Price Target$3.00 Potential Upside/Downside+455.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.53 million Net Margins-434.44% Pretax Margin-468.86% Return on Equity-89.36% Return on Assets-36.39% Debt Debt-to-Equity RatioN/A Current Ratio6.89 Quick Ratio6.89 Sales & Book Value Annual Sales$14.56 million Price / Sales19.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book5.92Miscellaneous Outstanding Shares249,300,000Free Float187,721,000Market Cap$280.46 million OptionableNot Optionable Beta1.51 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NYSEAMERICAN:LCTX) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersPass by August 7… or wait until 2027?Right now, your phone is recording exactly where you are. It does this roughly every two minutes. Precise coor...Crypto 101 Media | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX just minted 4,400 millionairesSpaceX's $1.75 trillion IPO turned more than 4400 employees into millionaires, according to The New York Times...The Oxford Club | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredSell SpaceX Now. Buy This Instead.Rob Spivey traveled to SpaceX's Starbase, Texas headquarters to uncover what Wall Street missed in the company...Altimetry | SponsoredEye-opening video on new space economyGoldman Sachs is calling it the Second Space Age, with projections of up to 10 trillion dollars flowing into t...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
